Ronald E. Pauli

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL.

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL

Sagent Holdings Co. operates as an injectable pharmaceutical company that develops and sources products which it sells in the U.S. through its sales and marketing team. It primarily focuses on generic injectable pharmaceuticals. The company currently offers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Sagent Holdings was founded in 2006 and is headquartered in Schaumburg, IL.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL